

AIM HIGHER



# Eurostars-2


Horizon 2020 'Health, demographic change and wellbeing'

**Matteo Fedeli**  
Eurostars Project Officer  
EUREKA Secretariat

**Brussels, 08 July 2016**

Eurostars is a joint programme between more than 30  
EUREKA member countries and the European Union





# EUREKA instruments

Over  
40 countries





---

**Joint  
programme**  
between  
EUREKA  
and EU



---

Dedicated  
to **R&D-**  
**performing**  
**SMEs**



---

**Market-**  
**oriented**



---

**Bottom-up**



---

**International  
cooperation**

## 36 countries

 Austria	 Greece	 Poland
 Bulgaria	 Hungary	 Portugal
 Belgium	 Iceland	 Romania
 Canada	 Ireland	 Slovak Republic
 Croatia	 Israel	 Slovenia
 Cyprus	 Italy	 South Africa
 Czech Republic	 Latvia	 South Korea
 Denmark	 Lithuania	 Spain
 Estonia	 Luxembourg	 Sweden
 Finland	 Malta	 Switzerland
 France	 The Netherlands	 Turkey
 Germany	 Norway	 United Kingdom



1.148 billion

Eurostars total public budget 2014-2020



75%

+

25%



EUROSTARS  
COUNTRIES  
CONTRIBUTION



EU  
CONTRIBUTION

PROJECTS SUBMITTED  
CUT-OFF 1-5

30%  
SUCCESS RATE

PROJECTS FUNDED  
CUT-OFF 1-5



1,553

NUMBER OF APPLICATIONS



472

NUMBER OF APPROVED PROJECTS



4,951

NUMBER OF APPLICANTS



1,511

NUMBER OF PARTICIPANTS



2.0 BILLION €  
TOTAL COSTS OF  
APPLICATIONS



675 MILLION €  
TOTAL COSTS OF  
APPLICATIONS FUNDED





38  
COUNTRIES INVOLVED

290 MILLION €  
ESTIMATED PUBLIC  
FUNDING




464 applications (30% of the total)  
 163 funded projects (35% success rate, 89% of projects above threshold)  
 533 participants from 26 countries  
 €270m public-private investment














## EUROSTARS SME PROFILE



50%

At least 50% of the job done by SMEs



64%

R&D-performing SMEs



< 50


83%

SMEs have less than 50 employees



40%

SMEs workforce is dedicated to R&D activities



Market introduction is foreseen within 2 years after project completion



**3–4 participants**



**2–3 countries**



average duration


**29 months**




average project cost

**€1.4 million**











Project leader is an **R&D-performing SME** from a Eurostars country



**At least 2 Participants**

- Autonomous entities
- Legal entities from **at least 2 Eurostars countries**



**SMEs** are in the **driving seat**

**International balance**



**Project duration** is max. **3 years**

**Market introduction** within **2 years**

## E1 - Consortium Leader is an R&D-performing SME

Company Category	Staff Headcount	Turnover	or	Balance Sheet Total
<b>Medium-sized</b>	<250	≤ € 50 m		≤ € 43 m
<b>Small</b>	<50	≤ € 10 m		≤ € 10 m
<b>Micro</b>	<10	≤ € 2 m		≤ € 2 m

According to EUREKA criteria, main factors determining whether a company is an R&D SME are:

SME Headcount (where X is the number of FTE)	Minimum number of FTEs dedicated to R&D	or	Minimum % of FTEs dedicated to R&D	or	Minimum % of Turnover dedicated to R&D
	whichever is fewer				
$0 < X \leq 100$	5.0	or	10.00 %	or	10.00 %
$100 < X < 250$	10.0	or	10.00 %	or	10.00 %

\* FTE = Full time equivalent

## E9: Market introduction is within 24.0 months of the project's completion

The market introduction of the major project result is planned to occur within 24.0 months of the completion of the project

In the case of biotechnology, biomedical or medical projects, the start of clinical trials is planned to occur within 24.0 months of project completion

### Calculation:

The time difference between the planned end of the project and planned market entry of the main product/process/service (as mentioned within the application) is calculated

### Consideration:

This will also form part of the evaluation, with the quoted figure in the application being evaluated with respect to its feasibility



## QUALITY AND EFFICIENCY OF THE IMPLEMENTATION: BASIC ASSESSMENT

- Quality of the consortium
- Added value through co-operation
- Realistic and clearly defined Project management & planning
- Reasonable cost structure



## EXCELLENCE: INNOVATION AND R&D


- Degree of Innovation
- New applied knowledge
- Level of Technical Challenge
- Technological achievability & Risk



## IMPACT: MARKET & COMMERCIALISATION


- Market size
- Market access and risk
- Competitive advantage
- Clear and realistic commercialisation plans
- Time to market

## ON EUROPEAN LEVEL




## SIMULTANEOUSLY

## ON NATIONAL LEVEL







- Only projects rated **above the quality thresholds** are recommended for funding
- The funding of projects is following the ranking list until **national budget exhaustion**
- The funding of partners is based on **the national funding rules**



## Time-to-contract is within 4 to 7 months









## SPINIT instrument to run quick blood test

- SPINIT (with disposable microfluidic cartridges) is a device which is neither expensive nor bulky and which can detect blood sample infections in minutes
- Doctors can now do in one consultation what could have taken a hospital days to perform
- SPINIT uses laser beam technology to read the blood on the disk and scan it for specific infections

### Countries >

The Netherlands, Portugal

Cost: 1.6 M€

The organisations continue to work together and are planning to expand SPINIT's capabilities to be able to detect an even wider range of diseases including diabetes



Aim Higher

# Matteo Fedeli

matteo.fedeli@eurekanetwork.org

Eurostars Project Officer  
EUREKA Secretariat



applications@eurostars-eureka.eu

Cut-off 6: **15 September 2016**

Good luck!



More info: [www.eurostars-eureka.eu](http://www.eurostars-eureka.eu)  
Contact: [www.eurostars-eureka.eu/home/contactus](http://www.eurostars-eureka.eu/home/contactus)